Frankfurt - Delayed Quote EUR
Vistin Pharma ASA (VP4.F)
2.1000
+0.1150
+(5.79%)
At close: April 25 at 10:37:41 AM GMT+2
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Magnus Tolleshaug | CEO, Chief Commercial Officer & Commercial Director | 188.69k | -- | -- |
| Mr. Alexander Karlsen | Chief Financial Officer | 197.38k | -- | -- |
| Mr. Vegard Heggem | Chief Operating Officer | 183.55k | -- | -- |
| Eivind Egeli | Director of Technical Service & Sales | -- | -- | -- |
Vistin Pharma ASA
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Corporate Governance
Vistin Pharma ASA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
April 25, 2025 at 5:35 AM UTC
Vistin Pharma ASA Earnings Date
June 4, 2025 at 12:00 AM UTC
Ex-Dividend Date
Recent Events
Recent Events Information Not Available